AnnexinA6 (AnxA6), a Ca<sup>2+</sup>-dependent phospholipid-binding protein, has been extensively reported as an essential target in mineralization-related diseases such as osteoporosis, osteoarthritis, atherosclerosis, osteosarcoma, and calcific aortic valve disease. This evidence concerns the gene ANXA6 and aortic valve calcification.